Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib + Pemetrexed in Advanced NSCLC
NCT00516100Phase 2Unknown
- Sponsor
- Aptium Oncology
- Start
- Jan 2006
- Primary completion
- Jan 2010
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib in non-small cell lung cancer (NSCLC), sponsored by Aptium Oncology. Primary endpoints: Maximum Tolerated Dose at 18 weeks, Objective Response Rate at 1 year and 3 more. Status: unknown.
02
Drugs
bortezomib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00516100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00516100.